Literature DB >> 33829324

Protective effects of berberine on senile osteoporosis in mice.

Qing-Chang Chen1, Yuan-Lin Pu2, Jing Bi2, Yan Zhang3.   

Abstract

INTRODUCTION: The incidence of osteoporosis is positively correlated with age. Berberine has been reported to treat osteoporosis due to its beneficial actions on bone formation. However, the direct effects of berberine on senile osteoporosis remain unclear. The present study investigated the protective effects of berberine on senile osteoporosis in mice and preliminarily evaluated its potential mechanism.
MATERIALS AND METHODS: 20-month-old male C57BL/6 J mice were used as senile osteoporosis mouse model and treated with strontium ranelate (SR) or berberine or solvent control by daily gavage for 2 months. Thereafter, bone mass and microstructure parameters were assessed. Histological staining was performed to identify the osteogenic, adipogenic and osteoclastic activity of bone tissue. Moreover, role of cAMP/PKA/CREB signaling pathway in berberine affecting bone marrow mesenchymal stem cells (BMSCs) differentiation was clarified by enzyme-linked immunosorbent assay and western blot analysis.
RESULTS: The results showed that the SR-treated group displayed a high trabecular bone mass phenotype. For mice administrated with berberine, cancellous bone mass was upregulated in a dose-dependent manner, as indicated by gradually increased bone mass, trabecular bone volume fraction and trabecular number. Furthermore, berberine promotes osteogenic and inhibits adipogenic differentiation of BMSCs via cAMP/PKA/CREB signaling. Also, bone resorption effect becomes more obvious with increasing dose of berberine in vitro.
CONCLUSION: The present results suggest that berberine exerts potent bone protective effects by promoting bone formation, inhibiting marrow fat accumulation and bone resorption. This effect may be achieved through cAMP/PKA/CREB signaling pathway.

Entities:  

Keywords:  Berberine; Bone marrow mesenchymal stem cells; CAMP; CREB; Osteoblasts; Osteoporosis; PKA

Year:  2021        PMID: 33829324     DOI: 10.1007/s00774-021-01225-2

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  2 in total

1.  Berberine alleviates oxidative stress in rats with osteoporosis through receptor activator of NF-kB/receptor activator of NF-kB ligand/osteoprotegerin (RANK/RANKL/OPG) pathway.

Authors:  Xiao-Feng He; Long Zhang; Chun-Hua Zhang; Con-Ran Zhao; Heng Li; Ling-Fei Zhang; Guo-Feng Tian; Ming-Feng Guo; Zheng Dai; Fu-Ge Sui
Journal:  Bosn J Basic Med Sci       Date:  2017-11-20       Impact factor: 3.363

Review 2.  Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus.

Authors:  Zheng Li; Ya-Na Geng; Jian-Dong Jiang; Wei-Jia Kong
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-11       Impact factor: 2.629

  2 in total
  2 in total

Review 1.  Targeting Sirt1, AMPK, Nrf2, CK2, and Soluble Guanylate Cyclase with Nutraceuticals: A Practical Strategy for Preserving Bone Mass.

Authors:  Mark F McCarty; Lidianys Lewis Lujan; Simon Iloki Assanga
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

Review 2.  Effects and mechanisms of natural alkaloids for prevention and treatment of osteoporosis.

Authors:  Bingfeng Lin; Pingcui Xu; Juan Zheng; Xuehui Deng; Qitao Ye; Zhongping Huang; Nani Wang
Journal:  Front Pharmacol       Date:  2022-09-23       Impact factor: 5.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.